Firalis Molecular Precision provides to its customers a broad range of technologies to help them scale by increasing their analytical capacities in the most flexible and customizable way.
We are an official service provider for Olink technologies, HTG EdgeSeq technologies, 10X genomics single cell analysis and Vizgen MERSCOPE technology.

Firalis Molecular Precision is the preferred partner for patient’s sample management thanks to a strong expertise in protocol design, biobanking, and multidimensional samples analysis. Whether it is in the patient’s perspective for diagnostic, prognostic, prediction and monitoring of the disease progression; or from the drug’s perspective to evaluate toxicity and efficiency.

Beyond its multi-omic approach, analytical capacities and scientific expertise, Firalis group is an end-to-end partner which offers clinical qualification, biobanking infrastructure, assay development, bioanalytical testing, data analysis and production facilities to empower your team and fasten your projects.

Genomics:
Firalis Molecular Precision is a French high throughput sequencing center equipped with the latest disruptive technologies. We provide all the platforms and experts required to perform genomic and transcriptomic analysis from DNA/RNA extraction to qPCR or DNA/RNA sequencing according to your requirements in terms of price, sensibility, analytes and acquisition time.
In addition, the cutting-edge single cell analysis system brings powerful oncological section analysis, allowing study and characterization of the Tumor Microenvironment on a cell-by-cell basis.
Our company offers a complete range of genomic analysis including detection of SNPs, CNVs, variants, ctDNA, gene identification, species identification, and genome structural organization. About transcriptomic, we provide whole transcriptomes to targeted sequencing analysis, allowing identification of novel transcripts, alternative splicing and differential gene transcription quantification. The characterization of rare cell types and biomarkers is also assessed on a cell-by-cell basis.

Proteomics:
When it comes to proteomic, our scientific team offers a large panel of services, ranging from large screening and new drug target discovery (Olink Explore 3072 proteins in 1 uL) to target validation and monitoring with extremely sensitive technologies such as the Quanterix SR-X and SP-X. More than a hundred of analytes are already validated on our platforms.

Firalis group is certified ISO 13485 (GMP compliant) and ISO 9001 for the development and production of CE-marked assays, certified NF S 96-900 for its biobank and accredited ISO 17025 (GCLP compliant) for testing laboratory.